Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDX 1135

Drug Profile

CDX 1135

Alternative Names: BRL 55730; CDX-1135; sCR1; Soluble complement receptor 1; Soluble complement receptor type 1; Soluble CR1; TP 10HD; TP10; YM 203

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVANT Immunotherapeutics
  • Developer Celldex Therapeutics Inc
  • Class Anti-ischaemics; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reperfusion injury
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Allotransplant rejection; Disseminated intravascular coagulation; Lung transplant rejection; Membranoproliferative glomerulonephritis; Multiple sclerosis; Reperfusion injury; Rheumatoid arthritis; Systemic lupus erythematosus; Xenotransplant rejection

Most Recent Events

  • 15 Apr 2014 Discontinued - Phase-I for Membranoproliferative glomerulonephritis in USA (IV)
  • 15 Apr 2014 Discontinued - Phase-II for Allotransplant rejection in USA (Parenteral)
  • 05 Mar 2014 Celldex Therapeutics terminates enrolment in a phase I trial in Membranoproliferative glomerulonephritis (early-stage disease, in children, adolescents and adults) in USA (NCT01791686)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top